Evidence map›Paper›PMID 26456960›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium.

Olga V Pankova, Evgeny V Denisov, Anastasia A Ponomaryova, Tatiana S Gerashchenko, Sergey A Tuzikov, Vladimir M Perelmuter

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Olga V PankovaDepartment of Pathological Anatomy and Cytology, Tomsk Cancer Research Institute, Kooperativny Str. 5, Tomsk, Russian Federation, 634050.
Evgeny V DenisovLaboratory of Molecular Oncology and Immunology, Tomsk Cancer Research Institute, Kooperativny Str. 5, Tomsk, Russian Federation, 634050. d_evgeniy@oncology.tomsk.ru.
Anastasia A PonomaryovaLaboratory of Molecular Oncology and Immunology, Tomsk Cancer Research Institute, Kooperativny Str. 5, Tomsk, Russian Federation, 634050.
Tatiana S GerashchenkoLaboratory of Molecular Oncology and Immunology, Tomsk Cancer Research Institute, Kooperativny Str. 5, Tomsk, Russian Federation, 634050.
Sergey A TuzikovDepartment of Thoracoabdominal Oncology, Tomsk Cancer Research Institute, Kooperativny Str. 5, Tomsk, Russian Federation, 634050.
Vladimir M PerelmuterDepartment of Pathological Anatomy and Cytology, Tomsk Cancer Research Institute, Kooperativny Str. 5, Tomsk, Russian Federation, 634050.
Tomsk Cancer Research Institute · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrences occur in 30 % of lung cancer patients after radical therapy; however, known prognostic factors are not always effective. In this study, we investigated whether the frequency of squamous non-small cell lung cancer (NSCLC) recurrence depends on the presence of reactive lesions in tumor-adjacent bronchial epithelium. Specimens of adjacent lung tissue from 104 patients with squamous NSCLC were used for the determination of basal cell hyperplasia (BCH) and squamous metaplasia (SM) and for the analysis of the expression of Ki-67, p53, Bcl-2, and CD138. We found that recurrence was observed in 36.7 % of patients with BCH combined with SM (BCH + SM+) in the same bronchus, compared with 1.8 % in patients with isolated BCH (BCH + SM-; odds ratio (OR) 31.26, 95 % confidence interval (CI) 3.77-258.60; p = 0.00002). The percentage of Ki-67-positive cells was significantly higher in BCH + SM+ than in BCH + SM- (34.9 vs. 18.3 %; effect size 2.86, 95 % CI 2.23-3.47; p = 0.003). P53 expression was also more significant in BCH + SM+ than in BCH + SM- (14.4 vs. 9.6 %; effect size 1.22, 95 % CI 0.69-1.76; p = 0.0008). In contrast, CD138 expression was lower in BCH + SM+ than in BCH + SM- (21.8 vs. 38.5 %; effect size -6.26, 95 % CI -7.31 to -5.22; p = 0.003). Based on our results, we concluded that the co-presence of reactive bronchial lesions is associated with the development of recurrent squamous NSCLC and may be a negative prognostic indicator. In addition, significant differences in Ki-67, p53, and CD138 expression exist between isolated BCH and BCH combined with SM that probably reflect part of biological differences, which could relate to the mechanism of lung cancer recurrence.

Indexed as

Neoplasm Recurrence, LocalAdultAgedBiomarkers, TumorBronchiCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellEpitheliumHumansHyperplasiaImmunohistochemistryKi-67 AntigenMetaplasiaMiddle AgedOutcome Assessment, Health CareProto-Oncogene Proteins c-bcl-2Biomarkers, TumorKi-67 AntigenProto-Oncogene Proteins c-bcl-2Syndecan-1TP53 protein, humanTumor Suppressor Protein p53HyperplasiaImmunohistochemistryLung cancerMetaplasiaRecurrence

Identifiers

PMID26456960
OpenAlexW1936250521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.